Vericel Corporation (VCEL) |
|
28.47 -0.34 (-1.18%)
|
03-24 11:15 |
|
Open: |
28.51 |
Pre. Close: |
28.81 |
|
High:
|
28.65 |
Low:
|
28.04 |
|
Volume:
|
31,065 |
Market Cap:
|
1,348(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 10:48:35 AM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 35.27 One year: 36.92 |
| Support: |
Support1: 27.92 Support2: 23.22 |
| Resistance: |
Resistance1: 30.2 Resistance2: 31.61 |
| Pivot: |
29.83  |
| Moving Average: |
MA(5): 29.19 MA(20): 30.01
MA(100): 26.61  MA(250): 27.38 |
| MACD: |
MACD(12,26): -0.1 Signal(9): 0.2 |
| Stochastic oscillator: |
%K(14,3): 16.8 %D(3): 31.5 |
| RSI: |
RSI(14): 44.1 |
| 52-week: |
High: 40.34 Low: 17.29 |
| Average Vol(K): |
3-Month: 415 (K) 10-Days: 374 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ VCEL ] has closed above bottom band by 10.3%. Bollinger Bands are 32.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
29.33 - 29.47 |
29.47 - 29.6 |
|
Low:
|
28.01 - 28.16 |
28.16 - 28.31 |
|
Close:
|
28.55 - 28.8 |
28.8 - 29.03 |
|
Company Description |
|
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. |
Headline News |
Sun, 05 Mar 2023
Gamco Investors INC. ET AL acquires 11,185 shares of Vericel Co ... - Best Stocks
Fri, 03 Mar 2023
Vericel Corp (VCEL) Stock: What Does the Chart Say Friday? - InvestorsObserver
Tue, 28 Feb 2023
Vericel to Present at the Canaccord Genuity Musculoskeletal ... - GlobeNewswire
Tue, 28 Feb 2023
Vericel Earnings Perspective: Return On Capital Employed - Vericel (NASDAQ:VCEL) - Benzinga
Thu, 23 Feb 2023
Vericel Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Full-Year 2023 Financial Guidance - Yahoo Finance
Thu, 23 Feb 2023
Vericel Corp Ord earnings beat by $0.08, revenue fell short of ... - Investing.com India
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
47 (M) |
| Shares Float |
44 (M) |
|
% Held by Insiders
|
0.7 (%) |
|
% Held by Institutions
|
112.6 (%) |
|
Shares Short
|
5,830 (K) |
|
Shares Short P.Month
|
6,110 (K) |
Stock Financials |
|
EPS
|
0.05 |
|
EPS Est Next Qtl
|
-0.1 |
|
EPS Est This Year
|
-0.63 |
|
EPS Est Next Year
|
-0.38 |
|
Book Value (p.s.)
|
2.93 |
|
Profit Margin (%)
|
-11.4 |
|
Operating Margin (%)
|
-12 |
|
Return on Assets (ttm)
|
-5.1 |
|
Return on Equity (ttm)
|
-10.9 |
|
Qtrly Rev. Growth
|
11.6 |
|
Gross Profit (p.s.)
|
2.24 |
|
Sales Per Share
|
3.37 |
|
EBITDA (p.s.)
|
-0.33 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
21 (M) |
|
Levered Free Cash Flow
|
17 (M) |
Stock Valuations |
|
PE Ratio
|
475.33 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
9.73 |
|
Price to Sales
|
8.45 |
|
Price to Cash Flow
|
63.34 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
